Samsung Biologics Participates in 2026 PEGS Boston, USA

Actively Promoting Contract Research and Development (CRDO) Capabilities

Samsung Biologics announced on May 13 that it participated in the global biopharmaceutical technology conference 'Protein & Antibody Engineering Summit (PEGS) Boston' to expand its engagement with global clients. The company actively promoted its Contract Research and Development Organization (CRDO) capabilities, including know-how to enhance efficiency and the likelihood of success in anticancer drug development.

PEGS (Protein & Antibody Engineering Summit) Boston is the world’s largest conference for protein and antibody pharmaceuticals, bringing together more than 2,500 industry experts to discuss the latest biopharmaceutical technologies. The event is held annually in Boston, Massachusetts, every May, and this year it runs for five days from May 11 to 15 (local time). During the summit, Samsung Biologics operates a dedicated meeting room and holds active business meetings with global pharmaceutical companies.

On May 12, Samsung Biologics hosted a luncheon presentation titled "Advancing Oncology Drug Discovery through Samsung Organoids and Integrated CDO Capabilities." Sehee Kim, Head of the Organoid Technology Group at the CDO Development Center, introduced strategies and know-how to support clients in efficient anticancer drug development, focusing on Samsung Organoids and the development suitability assessment platform 'DEVELOPICK®.'

Launched officially in June last year, Samsung Organoids is a service that utilizes organoids, which closely mimic actual patient tumors, to pre-validate the efficacy of anticancer drug candidates. The service especially focuses on screening anticancer drug candidates based on 'patient-derived organoids.' This allows for precision evaluations that reflect diverse patient characteristics, enabling comparison and analysis of drug efficacy across various tumor types and selecting promising candidates, thereby reducing the risk of failure in the early stages of development.

DEVELOPICK is a development potential assessment platform that has evolved to version 3.0 since its initial launch in October 2022. It precisely analyzes the characteristics of candidate molecules using only small amounts of protein, allowing for the optimal selection of candidates. By evaluating both efficacy and development potential, the platform helps accelerate drug development and improve the probability of success.

In addition, Samsung Biologics has established a total of nine CDO technology platforms to provide tailored services for clients. These include DEVELOPICK, the high-concentration formulation development platform S-HiCon™, the proprietary cell line platform S-CHOice®, and the bispecific antibody platform S-DUAL®, enabling customized CDO services from early development through Investigational New Drug (IND) application.

James Choi, Executive Vice President and Head of Business Support at Samsung Biologics, stated, “Samsung Biologics has continuously enhanced its capabilities to maximize our clients’ success from early candidate discovery through clinical development and commercialization. Going forward, we will continue to meet diverse client needs with differentiated platforms.”

Meanwhile, Samsung Biologics has been consistently expanding client engagement by participating in various global conferences throughout this year. In March, the company attended DCAT Week, and in April, it met with various clients at the American Association for Cancer Research (AACR) annual meeting. In June, Samsung Biologics plans to further strengthen its order intake activities at the world’s largest bio-pharmaceutical exhibition, the 2026 BIO International Convention (BIO USA), to be held in San Diego, USA.